{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:49:07Z","timestamp":1786787347616,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Center for Companion Animal Health, School of Veterinary Medicine, University of California"},{"name":"National Cancer Institute of the National Institutes of Health","award":["K12CA138464"],"award-info":[{"award-number":["K12CA138464"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:p>The goals of this retrospective study were to determine the patient characteristics of dogs with high\u2010grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow\u2010up information available. The most common clinical signs included lethargy, anorexia and polyuria\/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T\u2010cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (<jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>) lymphoma classification scheme. The overall progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) were 133 and 183\u2009days, respectively. Treatment with a <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> (cyclophosphamide, doxorubicin, vincristine, prednisone) protocol was associated with an improved <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> (144\u2009days) and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (194\u2009days) when compared with dogs that received other medical therapies (<jats:italic>P<\/jats:italic>\u2009=\u2009.005 and <jats:italic>P<\/jats:italic>\u2009=\u2009.002, respectively); the absence of pleural effusion at diagnosis was associated with an increased <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> but not <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>. These results suggest that while the prognosis for dogs with mediastinal lymphoma is poor, survival may be improved with treatment using a <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010based protocol.<\/jats:p>","DOI":"10.1111\/vco.12331","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T03:12:41Z","timestamp":1498705961000},"source":"Crossref","is-referenced-by-count":20,"title":["Patient characteristics, prognostic factors and outcome of dogs with high\u2010grade primary mediastinal lymphoma"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-5841","authenticated-orcid":false,"given":"E. L.","family":"Moore","sequence":"first","affiliation":[{"name":"William R. Pritchard Veterinary Medical Teaching Hospital School of Veterinary Medicine, University of California, Davis  Davis California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Vernau","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology &amp; Immunology School of Veterinary Medicine, University of California, Davis  Davis California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"Rebhun","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences School of Veterinary Medicine, University of California, Davis  Davis California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0324-445X","authenticated-orcid":false,"given":"K. A.","family":"Skorupski","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences School of Veterinary Medicine, University of California, Davis  Davis California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-8298","authenticated-orcid":false,"given":"J. H.","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences School of Veterinary Medicine, University of California, Davis  Davis California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"608","volume-title":"Withrow & MacEwen's Small Animal Clinical Oncology","author":"Vail DM","year":"2013"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.2010.01683.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.1997.tb00863.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2010.00230.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12304"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1991.tb03133.x"},{"issue":"7","key":"e_1_2_7_8_1","first-page":"807","article-title":"Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non\u2010Hodgkin's lymphoma","volume":"24","author":"Vail DM","year":"1996","journal-title":"Exp Hematol"},{"issue":"2","key":"e_1_2_7_9_1","first-page":"169","article-title":"Immunophenotypic characterization of canine lymphoproliferative disorders","volume":"11","author":"Ruslander DA","year":"1997","journal-title":"In Vivo"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/591753"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2000.tb02224.x"},{"issue":"1","key":"e_1_2_7_12_1","first-page":"52","article-title":"Evaluation of an actinomycin\u2010D\u2010containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma","volume":"47","author":"Siedlecki CT","year":"2006","journal-title":"Can Vet J"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2016.03.003"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12163"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2009.0289.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.994604"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12722"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.11.004"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2011.12.019"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2009.00200.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810379428"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2009.0353.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2001.tb02328.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2003.10.009"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2008.05.009"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.12.003"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0585-x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.889850"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0110"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24172"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.09.017"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24325"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12127"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvco.12331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T19:49:21Z","timestamp":1694980161000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/vco.12331"],"URL":"https:\/\/doi.org\/10.1111\/vco.12331","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}